Deflazacort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than predni sone. In mdx mice, deflazacort treatment augments repair and growth of new muscle fibers. We tested the hypothesis that deflazacort improves muscle function and promotes repair by increasing myogenic cell proliferation and fiber differentiation, mdx mice (3.5 weeks old) were treated with deflazacort (1.2 mg/kg) or vehicle for 4 weeks. Forelimb grip strength was measured. After 4 weeks, the right tibialis anterior muscle (TA) was crush injured to induce synchronous regeneration. DNA was labeled using different markers 24 and 2 h before collecting tissues 4 days after injury. The expression of creatine kinase (CK) isoforms, laminin-2 (merosin) mRNA and protein, and proliferation by myogenic cells were measured and satellite cells were identified by immunolocalization of c-met receptor. Peak grip strength increased 15% within 10 days of treatment, and was maintained up to 6 weeks after the end of treatment in a second experiment. Expression of CK MM in the regenerating TA rose from 46% to 55% of total CK activity after deflazacort treatment. Satellite cells were more numerous and appeared earlier on new fibers, in concert with a threefold increase in proliferation by myogenin+ (but not MyoD+) myoblasts. a2-Laminin mRNA expression and protein increased 1.3-5.5-fold relative to MM CK in regenerating and dystrophic TA, respectively. These studies support the hypothesis that deflazacort promotes functional gains, myogenic differentiation, myoblast fusion, and laminin expression in regenerating dystrophic muscle. The potential to augment precursor specifi cation, strength, and possible membrane stability may be useful in directing long-term benefits for DMD patients and short-term amplification of precursors prior to myoblast transfer.
INTRODUCTION
Deflazacort and prednisone are both used to treat Du chenne muscular dystrophy (DMD) (4, 14, 19, 26) . While both have important side effects as glucocorticoids, de flazacort treatment results in significantly smaller loss of trabecular bone than prednisone (18) . Previous work from this laboratory has characterized the particular ef fects of deflazacort or prednisone treatment on dystro phy using the mdx mouse model of DMD. Limb mus cles in mdx mice show quite successful regeneration after the onset of dystrophic damage, while the dia phragm muscle exhibits more severe dystrophy similar to DMD (34) . Tissue inflammation was reduced in both limb and diaphragm muscle, and fibers were larger after deflazacort treatment (2) . Recently, less severe cardio myopathy and hypertrophy of cardiomyocytes were found in mdx mice after deflazacort (33) .
Deflazacort also promotes muscle regeneration after a crush injury, which is used in this laboratory to model synchronous repair in the tibialis anterior muscle (TA).
After 4 days' recovery, new myotubes were larger than in placebo-or prednisone-treated dystrophic mice. The incorporation of newly divided myoblasts into those myo tubes was also greater following deflazacort treatment for 4 weeks. However, the potential functional gains during deflazacort were not explored, and the scope of mechanisms underlying the treatment benefits to skeletal muscle repair after injury or during dystrophy was not addressed.
Different phenotypes of dystrophy in mdx mice are only partly explained by differences in proliferation by myogenic cells or cells expressing the mitogen, basic fibroblast growth factor (bFGF) (3) . For example, prolif eration by bFGF-expressing cells (including muscle and nonmuscle cells in tissue sections) was lower in dia phragm than TA, while the inverse was true for myo genic cells expressing myf5 mRNA (detected by in situ Accepted March 6, 2000. hybridization). Proliferation of cells expressing myf5, a regulatory gene expressed early in commitment to the muscle lineage (23) , was slightly greater in diaphragm than TA, while there were no differences in proliferation by cells expressing MyoD, MRF4, or myogenin mRNA. Those data suggested that nonmuscle tissues likely play an important part in preventing or slowing new muscle formation after repetitive injury in the diaphragm. In contrast, one of the differences between regenerating muscles in strains of mice with different repair pheno types was greater proliferation by myogenin+ cells (but not myf5+ cells) in relation to more effective regenera tion (21, 24) . Therefore, in some circumstances, changes in proliferation by committed or even differentiating myogenic precursor cells can partly account for distinct phenotypes.
Interestingly, the concentration of taurine, a protect ant molecule in excitable tissues (1, 5, 15, 29) , was found to be higher in correlation with the centronucleation in dex of repair in regenerating muscles. Taurine was also increased after deflazacort treatment and was higher in muscles with the most effective repair (22) , suggesting that improved membrane stability after treatment might help to spare dystrophin-deficient fibers from damage. Dystrophin is linked by the dystroglycan complex to laminin in the extracellular matrix (7, 12) , and laminin deficiency itself results in a severe form of dystrophy (28, 36, 37, 40) . Finally, laminin expression is reported to increase during glucocorticoid treatment (9, 16, 17, 31, 39) . This information led to the hypothesis that deflaza cort may improve the functional outcome of dystrophy and promote repair by increasing myogenic cell prolifer ation and laminin expression.
In order to address the deficiency in understanding of a drug in current use for DMD, we examined deflazacort effects on regeneration by studies of tissue histopathology, laminin expression, proliferation of myogenic cells, and bFGF expression in deflazacort-and placebo-treated mdx dystrophic mice. Before and during treatment, fore limb grip strength was determined using a calibrated force transducer (25) in order to determine the extent of functional improvement in dystrophic muscles after treatment. In double-blind experiments tissue expression was compared among diaphragm, the intact uncrushed TA muscle, and the regenerating region of the right TA 4 days after crush injury. Differentiation of myotubes was investigated through study of creatine kinase isoform expression in regenerating muscles according to Bischoff and Heintz (6) , who showed that the immature isoform (BB) shifts sequentially to MB and then to the mature muscle (MM) isoform during repair. By this in vestigation the short-term effects and longer range im pact of deflazacort treatment on dystrophy, function, and repair were tested. In a third experiment, animals were treated for 2 weeks during muscle strength testing, and then allowed to survive another 6 weeks without treatment to observe the persistence of drug treatment effects on mean grip strength. In this case, mean strength (from 12 measures, 4 trials of 3 pulls each) rather than mean peak strength (as recorded in the first experiment) was determined on at least weekly intervals for each animal as indicated between days -1/0 and days 56/57. Analysis of variance and Duncan's tests were used to determine significant differences between groups.
MATERIALS AND METHODS

Animal Treatment Protocol and Tissue Collection
Myogenic Cell Proliferation
The expression of mRNA for MyoD or myogenin was determined using in situ hybridization and digoxigenin-labeled riboprobes exactly as reported (10) . The in situ signal was not present in negative control sections incubated in the absence of probe, with RNAse pretreat ment or in the absence of anti-digoxigenin antibody as appropriate. In every case, sections from complete groups of deflazacort-and placebo-treated animals were processed together and accompanied by negative control sections. Immediately after the in situ protocol, sections were dried and prepared for autoradiography. Autoradio grams were exposed for 4 weeks and developed to iden 
RESULTS
Muscle Strength
The mean peak strength of forelimb grip (normalized to body weight) was significantly increased by deflaza cort treatment. In the first experiment, the mean peak strength was 15% higher after 10 days of treatment and the difference was maintained for the entire 4 weeks of treatment ( Fig. 1A) . At the end of the experiment for comparison, the mean peak strength of 8-week-old nor mal mice (C57B1/10) was 7.0 g/g, while age-matched dystrophic mice had 25% lower grip strength (5.3 g/g).
The mean strength at 8 weeks of age was 5.8 g/g for normal mice and 4.1 g/g for mdx mice (30% of normal).
In another experiment, deflazacort treatment was shortened to 2 weeks while strength tests were continued weekly for a further 6 weeks as means of examining any persistent treatment effects ( Fig. IB , n = 5 per group).
Here deflazacort treatment resulted in significantly in creased mean grip strength (normalized to body weight) by 10 days (not mean peak strength as in Experiment 1). The strength increase began early, was maintained for 2 weeks, and was significantly increased 1 week after the end of treatment. After that, mean strength dropped to the level of placebo-treated mice, and finally rose again to be significantly higher than placebo levels at 57 days (6 weeks after stopping treatment). Contrary to initial reasoning, the drop at 4 weeks was not concur rent with any difference in body weight between the two groups of animals at that time. Body weight of deflaza cort-treated mice was not significantly higher than pla cebo-treated mice (Fig. IC) . In a graph of individual strength records for four mice of the same experiment for deflazacort and placebo groups (n = 10) during 28 days of treatment. Peak strength was significandy higher for the deflazacort group as indicated (*). Peak strength for 56-day-old (age-matched) control mice is indicated by the circle (C). (B) Mean normalized strength (mean ± SEM, g per g body weight) for deflazacort-and placebo-treated mice (n = 5 per group) before and during 2 weeks of treatment, and continuing for 6 weeks after the end of treatment (up to 57 days).
Mean strength was significantly greater in the deflazacort group compared to placebo at 22 and 57 days (*). Mean strength showed a significant change (up or down) from the previous measure ment in the same group as indicated (• for deflazacort group, for placebo group) after Duncan's post hoc tests. Mean strength in 2-month-old normal control mice is indicated by the circle (C). Inset: Individual data for four deflazacort-treated mice in the first 3 weeks of Experiment B (mean strength, as a proportion of initial strength). There was a trend for the larger, most stable increase to occur in animals that responded early. (C) Body weight plotted over time for Experiment B. The slight increase in weight was consistent and did not account for strength changes seen in (B) after the end of treatment at 14 days. early strong response to maintain an improved strength.
Those mice that had a slower or smaller response did not maintain the rise in strength long after treatment had stopped. These data show that deflazacort produced an increase in peak and mean grip strength (normalized to body weight) within a short treatment interval, and that the effect generally persisted at least 6 weeks after the end of treatment.
Regeneration and Satellite Cells
After 4 weeks of deflazacort treatment, regions of in flammation and fiber necrosis were reduced in dystro phic muscles and myotubes were larger in regenerating muscle, as reported previously (2) . Satellite cells were identified by c-met immunostaining, and were present on intact fibers in muscles from placebo-and deflaza cort-treated groups ( Fig. 2A, B ). c-met+ mononuclear cells were also located in regions of regenerating muscle (Fig. 2C, D) , while new myotubes did not stain positive for c-met protein. c-met+ satellite cells were especially large and prominent on diaphragm fibers. Subjectively there were more frequent satellite cells on the surface of centrally nucleated fibers in muscles from the deflaza cort than the placebo group ( Fig. 2E, F) . On the new myotubes in regenerating muscle, c-met+ satellite cells were never present in muscle sections from placebotreated animals. By comparison, there were occasional c-met+ satellite cells observed on small new myotubes in comparable regions of regenerating muscle of defla zacort-treated mice (Fig. 2G, H) .
BrdU was incorporated into myotube nuclei (and other nuclei) in dystrophic muscles with and without crush injury (Fig. 3A-D The expression of bFGF mRNA was examined with in situ hybridization ( Fig. 4A-F None of the proliferating cells (labeled with silver grains) were positive for laminin mRNA in either treat ment group. No differences in the distribution of laminin mRNA expression were apparent between the two treat ment groups.
Myogenic Precursor Proliferation
The proportions of mononuclear cells in the regener ating TA that were labeled by silver grains (RAG+), by the in situ hybridisation signal (MRF+) for expression of either MyoD or myogenin transcript, or that were positive for both signals (RAG+/MRF+) were recorded for at least 300 cells per section, as illustrated and re ported earlier (3, 22) . Data (mean ± SEM) are presented in Table 1 .
In the MyoD in situ hybridization experiment (Table   1) genin-expressing cells (RAG+/MRF+) in deflazacorttreated mice was increased threefold over placebo (from 2.0% to 6.7%) ( Table 1 ). There was also a substantial increase in the number of proliferating mononuclear cells in regenerating muscle that were not positive for myogenin mRNA (from 9.2% to 30.5%) after deflaza cort treatment.
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Creatine Kinase Isoform Expression
The densitometry data of creatine kinase activity sep arated into isoforms showed a significant shift from im mature (BB and MB) to the mature MM CK isoform expression after 4 weeks of deflazacort treatment for both regenerating TA and diaphragm (chi-square, p < 0.01) (Fig. 5A) . Table 2 shows the distribution of CK isoforms in all three muscles. Total CK activity ranged from 134.3 pg P/mg muscle (regenerating TA, placebo) to 682.9 pg P/mg muscle (uncrushed TA, placebo).
Western and Northern Blots
Blots for laminin mRNA and protein from pooled samples of placebo-and deflazacort-treated mdx mus cles are shown in Figure 5B and C, respectively. After deflazacort treatment, the mean expression (from Exper iments A and B) of laminin mRNA was increased rela tive to placebo for both regenerating and uncrushed TA muscles but not for the diaphragm (Table 3) . Expression of mRNA relative to the MM CK activity representing differentiated muscle in the counterpart samples of Ex periment A was increased for all three muscles. The mean expression of laminin protein was greater in LTA and diaphragm, while RTA laminin was not increased 
DISCUSSION
The value of a particular therapy can be augmented by understanding drug effects on the tissue-specific pro cesses that underlie improved function. In the case of muscular dystrophy and muscle repair, deflazacort treat ment studies of the mdx mouse may provide a realistic potential range for expectations of treatment in human DMD. The current studies showed that deflazacort sig nificantly improved forelimb peak grip strength after In one study, satellite cells identified by morphology us ing the electron microscope (EM) were noted on some myotubes starting at 5 days and were common by 15 days after an injection of marcaine injury in rats, which induces more rapid repair than crush injury (13) . 
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